A Global Call for Urgent Leadership on Alzheimer’s and Brain Health

GLOBAL COMMUNIQUÉ

Published 5 November 2026 · Open for signature

We, the undersigned, including a former head of government, former ministers, legislators and leaders in global health, call on the governments of the world to act with urgency on Alzheimer’s disease as a global health priority, and to make prevention the foundation of that action.

The biological changes associated with Alzheimer’s disease begin ten to twenty years before the first symptoms. Science is now moving into that window at a transformative pace. Blood tests can increasingly detect the biological markers of the disease. The tools to identify people at increased risk are advancing rapidly. Artificial intelligence is accelerating all of it, from the discovery of biomarkers to the design of trials. The first disease-modifying therapies are approved for early symptomatic Alzheimer’s disease, and trials are now testing whether intervening before symptoms appear can stop the disease from taking hold. Nearly half of all dementia cases could be prevented or delayed by modifying risk factors over a lifetime. The opportunity to act before the disease takes hold is real, and it is now.

The cost of waiting is unsustainable. More than 57 million people were living with dementia in 2021; this number is projected to reach 152 million by 2050. The fastest increases will come in lower- and middle-income countries, particularly across Africa, Asia and Latin America, where health, care, data and social-protection systems are least equipped to absorb them. The global economic cost was estimated at $1.3 trillion in 2019, and the burden falls disproportionately on women, who represent the majority of people living with dementia and provide around 70 percent of care hours.

Alzheimer’s disease and related dementias represent a growing global health challenge, driven in large part by population ageing and demographic change. Investment in low-cost diagnostics and solutions to prevent Alzheimer’s is not a cost but an investment in the social and economic health of nations.

The economic impacts of innovative diagnostics and prevention solutions point in one direction. Decades of evidence in human development show that the return on public investment is maximised when the investment is made as early as possible, and that it decreases with each year of delay. Preventing or delaying dementia preserves years of healthy, independent life while reducing pressure on families, health systems and long-term care. Yet most health systems remain organized around diagnosing and managing disease only after it has become clinically apparent. We have an opportunity to move investment upstream, toward risk reduction, brain health and earlier detection and intervention. The prevention of dementia must be at the center of the global health agenda.

Governments have led before. Each of our countries has invested in this work, through national plans, research funding, or advocacy in international forums, and each of our countries is deeply affected by this disease. Internationally, the lead has passed from hand to hand. France made Alzheimer’s a national and European priority in 2008. The United Kingdom convened the G8 Dementia Summit in 2013 and created the World Dementia Council and catalyzed the annual Lausanne Conference. Japan put ageing and dementia at the centre of its G20 presidency in 2019. The Netherlands has convened regularly. Each of those moments mattered, yet none has created a sustainable path to prevention applicable throughout the G20 and beyond. The problem is not a shortage of commitment. It is that every advance has depended on a particular government at a particular moment, and none has outlived it. What this work requires is a platform that survives political cycles.

We therefore call on the G20, and on all governments, to:

  1. Make prevention the organizing principle of national Alzheimer’s and brain health policy, shifting from a model focused on managing established disease toward one that reaches people earlier.

  2. Establish a permanent G20 mechanism for Alzheimer’s prevention and brain health, bringing together governments, international organizations, scientific institutions, civil society and the private sector, with regular monitoring and accountability to ensure continuity beyond individual presidencies and political cycles.

  3. Direct the global artificial intelligence agenda towards brain health. Governments are now writing the rules that will shape the development and use of artificial intelligence. They must ensure that this technology is deliberately directed towards advancing our understanding of the brain, preventing diseases that impair cognitive abilities, and accelerating their early detection and treatment. AI is already accelerating biomarker discovery, clinical trial design and the detection of risk years before symptoms appear, and philanthropy and industry have begun to fund this work at scale. Governments should support this progress by facilitating access to population-scale health data under strong safeguards, establishing standards for validating AI-derived diagnostics, and ensuring that the resulting innovations reach lower- and middle-income countries rather than widening existing inequalities. An agenda that governs artificial intelligence without directing it towards human brain health and cognitive diseases is incomplete.

  4. Adopt a life-course approach to brain health, addressing modifiable risk and resilience factors from childhood through old age, with brain health embedded in ordinary preventive care alongside cardiovascular, metabolic and cancer risk.

  5. Ensure timely access to appropriate early detection and diagnosis, including validated blood-based biomarkers and emerging diagnostics, supported by professional education, evidence-based guidelines and reimbursement.

  6. Invest in the data and evidence needed to advance prevention, particularly in populations and regions where evidence remains limited. This must include greater attention to the specific biology, risk factors and experiences of women, who are disproportionately affected by Alzheimer’s disease and related dementias and bear a substantial share of the responsibility for providing care.

  7. Commit to global equity, so that innovation reaches lower- and middle-income countries on terms suited to local needs, rather than as an afterthought to wealthy nations.

The G20 has already recognized dementia as a global policy priority. Yet this commitment has not translated into a sustained framework for action. What is missing is continuity, implementation and accountability.

Science has shown us where the opportunity lies. It cannot bring prevention to the population. That requires political leadership that is consistent, cross-sector, global, and accountable to the patients and families who have waited long enough.

We commit our names to this call, and we invite the leaders of the world to join us.

This call originated at the thirteenth Lausanne Workshop on Alzheimer’s Disease in October 2026, initiated by Nora Berra, former Minister for Seniors and former Minister of Health of France. It remains open for signature.

SIGNATORIES

Nora Berra, MD, former Minister for Seniors and former Minister of Health, France (Initiator)

Ahmed Robleh Abdilleh, MD, former Minister for Health, Djibouti

Oumar Diouhé Bah, PharmD, former Minister for Health and Public Hygiene, Guinea

Modou Diagne Fada, former Minister for Health, Senegal

Assane Diop, former Minister for Health and Social Action, Senegal

Abdoulaye Diouf Sarr, former Minister for Health and Social Action, Senegal

Abdou Fall, former Minister for Health and Medical Prevention, Senegal

Julio Frenk, former Minister of Health of Mexico

Samira Friaa, MD, former Minister for Public Health, Tunisia

Chiril Gaburici, former Prime Minister of Moldova and former Minister of Economy and Infrastructure

Conny Helder, former Minister for Long-term Care and Sport and former Minister of Health, Welfare and Sport, the Netherlands

Dorothée Kinde-Gazzard, MD, former Minister for Health, Benin

Facundo Manes, former member of Argentina’s Chamber of Deputies and former Chair of its Committee on Science, Technology and Productive Innovation

Pierre Maudet, Geneva State Councillor for Health and Mobility, Switzerland

Moustafa Mijiyawa, MD, former Minister for Health and Public Hygiene, Togo

Mankeur Ndiaye, former Minister of Foreign Affairs of Senegal, former United Nations Under-Secretary-General and former Special Representative of the UN Secretary-General in the Central African Republic

Mabingué Ngom, former Regional Director for West and Central Africa, United Nations Population Fund (UNFPA)

Michel Sidibé, former Minister of Health and Social Affairs of Mali, Special Envoy for the African Medicines Agency, former United Nations Under-Secretary-General and former Executive Director of UNAIDS

Lia Tadesse Gebremedhin, MD, former Minister of Health of Ethiopia

Next
Next

Moving Alzheimer's Blood Tests from Early Adopters to Everyday Care